Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 593 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PRIME Clear all
Completed Phase 1Phase 2 Interventional Results available

Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

NCT01693601
View directory record Official record
Conditions
Myelofibrosis
Interventions
Panobinostat, Ruxolitinib
Drug
Lead sponsor
John Mascarenhas
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 24, 2026, 10:51 AM EDT
Terminated Not applicable Interventional

Enhancing Motivation in Recent Onset Schizophrenia

NCT01817387
View directory record Official record
Conditions
Schizophrenia
Interventions
PRIME, Cognitive Training
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
14 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer

NCT01417000
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
GVAX Pancreas, CRS-207, Cyclophosphamide
Biological · Drug
Lead sponsor
Aduro Biotech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Tampa, Florida • Baltimore, Maryland • Bethesda, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 24, 2026, 10:51 AM EDT
Terminated Phase 3 Interventional Results available

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

NCT04313881
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Magrolimab, Azacitidine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 1 Interventional

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

NCT00834665
View directory record Official record
Conditions
Multiple Myeloma
Interventions
hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 80 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 24, 2026, 10:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Opt-IVF for Personalized Medicine for Normal Responders

NCT07856082
View directory record Official record
Conditions
Ivf
Interventions
Opt-IVF, control
Device · Other
Lead sponsor
Urmila DIwekar
Industry
Eligibility
20 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 24, 2026, 10:51 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

NCT06022224
View directory record Official record
Conditions
COVID-19
Interventions
hAd5-S-Fusion+N-ETSD, Placebo (0.9% (w/v) saline)
Biological
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
16 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2024 · Synced Oct 24, 2026, 10:51 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

Optimized, Neuroplasticity-Enhanced-Depression (ONE-D) Transcranial Magnetic Stimulation (TMS) Treatment for Female Athletes With Co-morbid Depression and Concussion

NCT07507214
View directory record Official record
Conditions
Concussion, Depression
Interventions
ONE-D TMS protocol and d-cycloserine (125 mg)
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ocala, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 24, 2026, 10:51 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Assessment of Endogenous Oxalate Synthesis

NCT05229952
View directory record Official record
Conditions
Healthy, Kidney Stone, Obesity
Interventions
Low-oxalate controlled diet, Primed, continuous intravenous infusion of 13C2-oxalate
Dietary Supplement · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 24, 2026, 10:51 AM EDT
Suspended Not applicable Interventional

Neuroplasticity in Maternal Opioid Use Disorder (OUD)

NCT05495984
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
ERPs with electroencephalography (EEG), MIO
Behavioral
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 24, 2026, 10:51 AM EDT
Active, not recruiting Phase 1 Interventional

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

NCT04046445
View directory record Official record
Conditions
Colorectal Cancer, MSS, Stage IV Colon Cancer, Stage IV Rectal Cancer, Metastatic Colorectal Cancer, Liver Metastasis Colon Cancer
Interventions
ATP128, BI 754091, VSV-GP128
Drug
Lead sponsor
Amal Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma

NCT03542266
View directory record Official record
Conditions
Previously Untreated Peripheral T-cell Lymphoma
Interventions
CC-486 Administration, CHOP Administration
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Tampa, Florida • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2023 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected Adults

NCT00384787
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA009-00-VP, VRC-HIVADV014-00-VP
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 24, 2026, 10:51 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine

NCT03141138
View directory record Official record
Conditions
Dengue Virus
Interventions
TDENV-PIV, TDENV-LAV F17
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 42 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2021 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 3 Interventional

Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia

NCT00338832
View directory record Official record
Conditions
Schizophrenia
Interventions
Physically Ready for Invigorating Movement Every Day (PRIME), Program for Activity, Leisure Skills, and Socialization (PALSS)
Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
21 Years to 64 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 9, 2013 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants

NCT03343626
View directory record Official record
Conditions
Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions
Placebo, PIZV
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Phase 2 Interventional Results available

Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

NCT00076752
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
fludarabine phosphate, cyclophosphamide, Rituxan (rituximab), filgrastim, methylprednisolone, immunologic technique, laboratory biomarker analysis, autologous hematopoietic stem cell transplantation, Diphenhydramine, Mesna
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
15 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 24, 2026, 10:51 AM EDT
Terminated Not applicable Interventional Results available

Assessing Effects of Heparin Priming and Pass Number on Tissue Quality of Fine Needle Biopsies

NCT04764396
View directory record Official record
Conditions
Pancreas, Mass Lesion
Interventions
Heparin will be used for needle priming (BD PosiFlush™ Pre-Filled Heparin Lock Flush Syringe), Saline
Combination Product · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study of Priming Before Induction Termination of Pregnancy

NCT00495560
View directory record Official record
Conditions
Abortion, Induced, Abortion, Second Trimester
Interventions
Addition of misoprostol 25 mcg 12 hours before induction
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2008 · Synced Oct 24, 2026, 10:51 AM EDT
Terminated Phase 4 Interventional Results available

Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

NCT02035345
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Platinum Sensitive Ovarian Cancer
Interventions
Carboplatin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 24, 2026, 10:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Supplements on Stress Markers

NCT05592561
View directory record Official record
Conditions
Physiological Stress
Interventions
mental stress task
Other
Lead sponsor
Texas State University
Other
Eligibility
18 Years to 40 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Marcos, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 24, 2026, 10:51 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers

NCT00062530
View directory record Official record
Conditions
HIV Infections
Interventions
SCBaL/M9
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 24, 2026, 10:51 AM EDT